Medical was Stryker’s largest product and service line in fiscal 2025, bringing in $4.20B of $25.12B (17%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Medical | $3.03B | $3.46B | $3.85B | $4.20B | ||||||
| Endoscopy | $2.76B | $3.07B | $3.39B | $3.81B | ||||||
| Trauma & Extremities | $2.81B | $3.15B | $3.51B | $3.95B | ||||||
| Instruments | $2.25B | $2.53B | $2.83B | $3.18B | ||||||
| Knees | $2.00B | $2.27B | $2.45B | $2.66B | ||||||
| Neuro Cranial | $1.66B | $1.88B | $2.14B | $2.49B | ||||||
| Neurotechnology | — | — | — | — | ||||||
| Hips | $1.41B | $1.54B | $1.70B | $1.87B | ||||||
| Neurovascular | $1.20B | $1.23B | $1.31B | $1.97B | ||||||
| Spine | $733.00M | $713.00M | $707.00M | $185.00M | ||||||
| Other | $606.00M | $658.00M | $712.00M | $815.00M | ||||||
| Other Medsurg & Neurotechnology | — | — | — | — | ||||||
| Sustainability | — | — | — | — | ||||||
| Total | $18.45B | $20.50B | $22.60B | $25.12B |
Stryker brought in $25.12B from its 10 product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 11.2% from $22.60B in fiscal 2024. Medical was the largest at $4.20B (16.7%), ahead of Trauma & Extremities at $3.95B (15.7%) and Endoscopy at $3.81B (15.2%). The other seven lines brought in $13.16B combined.
Compared with fiscal 2024, Neurovascular grew fastest, up 50.6% to $1.97B. Every line above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these lines grew from $18.45B to $25.12B, a compound annual growth rate of 10.8%. Medical's share held steady at about 16.7%.
Medsurg & Neurotechnology was Stryker’s largest segment in fiscal 2025, bringing in $15.65B of $25.12B (62%).
| Segment | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medsurg & Neurotechnology | $10.89B | $12.16B | $13.52B | $15.65B | ||||||||||||||
| Orthopaedics | $7.56B | $8.34B | $9.08B | $9.47B | ||||||||||||||
| Orthopaedics & Spine | — | — | — | — | ||||||||||||||
| United States | — | — | — | — | ||||||||||||||
| Medsurg | — | — | — | — | ||||||||||||||
| Ortho | — | — | — | — | ||||||||||||||
| Neurotechnology & Spine | — | — | — | — | ||||||||||||||
| Europe, Middle East, Africa | — | — | — | — | ||||||||||||||
| Other European Countries | — | — | — | — | ||||||||||||||
| Asia Pacific | — | — | — | — | ||||||||||||||
| Other Foreign Countries | — | — | — | — | ||||||||||||||
| Ireland | — | — | — | — | ||||||||||||||
| Total | $18.45B | $20.50B | $22.60B | $25.12B |
Stryker brought in $25.12B from its two segments in fiscal 2025, the year ended December 31, 2025. That was up 11.2% from $22.60B in fiscal 2024. Medsurg & Neurotechnology was the largest at $15.65B (62.3%), ahead of Orthopaedics at $9.47B (37.7%).
Compared with fiscal 2024, Medsurg & Neurotechnology grew 15.7% to $15.65B and Orthopaedics grew 4.3% to $9.47B. From fiscal 2022 to 2025, combined revenue from these segments grew from $18.45B to $25.12B, a compound annual growth rate of 10.8%. Medsurg & Neurotechnology's share of the total rose from 59.0% to 62.3%.
United States was Stryker’s largest region in fiscal 2025, bringing in $19.01B of $25.12B (76%).
| Geography | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $13.64B | $15.26B | $16.94B | $19.01B | ||||||||||
| Europe, Middle East, Africa | $2.35B | $2.62B | $2.90B | $3.18B | ||||||||||
| Europe, Middle East, & Africa | — | — | — | — | ||||||||||
| Asia Pacific | $1.89B | $1.95B | $2.02B | $2.16B | ||||||||||
| Other Foreign Countries | $578.00M | $677.00M | $735.00M | $765.00M | ||||||||||
| Total | $18.45B | $20.50B | $22.60B | $25.12B |
Stryker brought in $25.12B from its four regions in fiscal 2025, the year ended December 31, 2025. That was up 11.2% from $22.60B in fiscal 2024. United States was the largest at $19.01B (75.7%), ahead of Europe, Middle East, Africa at $3.18B (12.7%) and Asia Pacific at $2.16B (8.6%). The remaining region, Other Foreign Countries, brought in $765.00M.
Compared with fiscal 2024, United States grew fastest, up 12.2% to $19.01B. Every region above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these regions grew from $18.45B to $25.12B, a compound annual growth rate of 10.8%. United States' share of the total rose from 73.9% to 75.7%.
Stryker (SYK) reports its revenue by product and service, by segment and by geography. In fiscal 2025, Medical was its largest product and service line, bringing in $4.20B (16.7% of the total), followed by Trauma & Extremities at $3.95B (15.7%).
Medical was Stryker's largest product and service line in fiscal 2025, bringing in $4.20B, or 16.7% of the $25.12B total across its 10 product and service lines.
Medsurg & Neurotechnology was Stryker's largest segment in fiscal 2025, bringing in $15.65B, or 62.3% of the $25.12B total across its two segments.
United States was Stryker's largest region in fiscal 2025, bringing in $19.01B, or 75.7% of the $25.12B total across its four regions.
Among Stryker's product and service lines that make up at least 2% of revenue, Neurovascular grew fastest in fiscal 2025, up 50.6% from $1.31B to $1.97B.
Every figure comes from Stryker's annual financial filings, as reported. Each line keeps the name Stryker gives it, and years follow its fiscal calendar.
Stryker's revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.